Information Provided By: 
Fly News Breaks for July 13, 2015
KYTH, DERM
Jul 13, 2015 | 08:00 EDT
Leerink analyst Seamus Fernandez recommends buying shares of Dermira now for catalysts in 2016 and the company's position as a dermatology takeover target. Given the increasing premiums paid for dermatology assets following the buyout of KYTHERA (KYTH), Dermira could be worth $60-$65 per share over the next 12-18 months, Fernandez tells investors this morning in a research note. He views the stock's risk/reward as "uniquely compelling" and keeps an Overweight rating on the name.
News For DERM;KYTH From the Last 2 Days
There are no results for your query DERM;KYTH
